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Introduction
Flavonoids are polyphenolic compounds abundant in the human diet, found in fruits, vegetables, nuts, seeds, and herbs. They are classified into several groups, including chalcones, flavones, flavonols, flavanones, anthocyanins, and isoflavonoids. Among them, flavones, mainly found in cereals and herbs, have a backbone of 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one). Several dietary flavones possess antitumor properties, including apigenin and luteolin (Singh et al. 2014) . Apigenin is known to inhibit tumorigenesis by activating transcription factor 3 (Li et al. 2009 ), inhibiting Akt (Lee et al. 2008) , and disrupting actin organization (Franzen et al. 2009 ). Luteolin induces apoptosis and inhibits cell proliferation, metastasis, and angiogenesis through inhibition of Akt and NF-jB , and causes cell cycle arrest at the G2/M phase (Wu et al. 2008) . Eupatorin is a natural flavone isolated from several plants including Tanacetum vulgare (Schinella et al. 1998) , Lantana montevidensis (Nagao et al. 2002) and Orthosiphon stamineus (Tezuka et al. 2000) . Eupatorin has been shown to exhibit antiproliferative activity in breast cancer cells expressing cytochrome P450 CYP1 enzymes (Androutsopoulos et al. 2008 ) and in several cancer cells through caspase activation (Doleckova et al. 2012; Estevez et al. 2014) . The p53 transcription factor functions as a tumor suppressor to inhibit tumor growth and induce apoptosis (Levine 1997; Chipuk et al. 2004) . However, the effect of eupatorin on the regulation of p53 remains largely unexplored. In the present study, we investigated the effect of eupatorin on the cell cycle and on apoptosis in HeLa human cervical carcinoma cells, in an attempt to evaluate its antitumor activity. Our data show that eupatorin arrests the cell cycle at the G2/M phase and induces apoptosis through the activation of the p53-dependent and p53-independent pathways.
Materials and methods

Chemicals
Eupatorin was obtained from Indofine Chemical Co. (USA). Other chemicals were purchased from SigmaAldrich (USA).
Cells and cell culture
HeLa human cervix carcinoma and HCT116 human colorectal carcinoma cells expressing the wild-type p53 (Jia et al. 1997) were obtained from the American Type Culture Collection (USA). Wild-type (p53 ?/? ) and p53-null (p53 -/-) HCT116 human colon cancer cells (Bunz et al. 1999) were described elsewhere (Shin et al. 2012) . Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum (Thermo Scientific Hyclone, USA) at 37°C in a 5 % CO 2 atmosphere.
Cell viability and cell proliferation assays
HeLa cells (2 9 10 3 cells/sample) were seeded on 96-well plates and treated with various concentrations of eupatorin for different time periods (0, 12, 24, and 48 h) . Cell viability assays were carried out using a Cell Counting Kit-8 TM (Dojindo Molecular Technologies, USA), according to manufacturer instructions. Absorbance was measured using an Emax Endpoint ELISA Microplate Reader (Molecular Devices, USA).
Flow cytometry for cell cycle analysis
Cellular DNA contents were analyzed by flow cytometry as previously described (Shin et al. 2012) . Briefly, HeLa cells were treated with 20 lM eupatorin for 12 and 24 h, fixed in 70 % (v/v) ethanol, washed twice in phosphate-buffered saline, and then stained with 50 lg/mL propidium iodide (PI) containing 0.1 % (v/v) Triton X-100, 0.1 mM ethylenediaminetetraacetic acid, and 50 lg/mL RNase A. Fluorescence was measured with a FACSCalibur flow cytometer (Becton-Dickinson Immunocytometry Systems, USA).
Analysis of apoptosis by Annexin V staining
HeLa cells or HCT116 cells (each 1 9 10 6 cells/sample) were treated with 20 lM eupatorin for 24 h. The cells were incubated with fluorescein isothiocyanate (FITC)-conjugated Annexin V according to the kit manufacturer's instructions (ChemoMetec, Denmark). PI was used to counterstain dead cells. FITC-and PI-positive cell numbers were analyzed by flow cytometry using a NucleoCounter NC-3000 (ChemoMetec).
Immunoblot analysis
Cells were lysed and immunoblotting was performed as described previously (Shin et al. 2013) . Antibodies specific to cleaved caspase-7, caspase-3, phospho-p53 (Serine-15), and poly(ADP-ribose) polymerase were obtained from Cell Signaling Technology (USA). Antibodies against Bax, p21, p53, and GAPDH were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Signals were detected using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, USA).
Luciferase promoter reporter assay
The generations of wild-type Bax promoter reporter, pBaxLuc(-478/?4), and mutant construct disrupted Egr-1-binding site, pBax-Luc(-478/?4)mtEgr1, were described elsewhere (Shin et al. 2011) . Bax promoter reporter assay was performed using the Dual-Glo Ò Luciferase Assay System as described previously (Shin et al. 2011 ).
Statistical analysis
Each experiment was repeated at least three times. Data are presented as the mean ± SD. Statistical comparisons were performed using the Student's t test or two-factor ANOVA using InStat version 3.0 software (GraphPad Software Inc., USA), as appropriate. A P value of \0.05 was considered statistically significant.
Results and discussion
To evaluate the cytotoxic effect of eupatorin (Fig. 1A) , exponentially growing HeLa cells were exposed to various concentrations of eupatorin (0, 20, 40, and 80 lM) for 24 and 48 h, and cell viability was measured using the Cell Counting Kit-8. Upon eupatorin exposure, a significant dose-and time-dependent decrease in cell viability was observed compared to untreated control cells (Fig. 1B) .
Next, we investigated whether eupatorin affected cell cycle progression. HeLa cells were treated with 20 lM eupatorin for 12 and 24 h, and the cell cycle profile was examined by flow cytometry. Upon eupatorin exposure, the proportion of G1-phase cells decreased in a time-dependent manner from 56.7 % at time 0 to 3.5 % at 12 h and 2.2 % at 24 h (Fig. 2) . Notably, the proportion of G2/M phase cells concomitantly increased (from 23.1 % at time 0-69.4 % at 12 h and 83.2 % at 24 h). These data suggest that eupatorin arrests the cell cycle at the G2/M phase.
Cyclin and cyclin-dependent kinase (Cdk) complexes are involved in the regulation of cell cycle progression. Upon receiving extracellular mitotic signals, the expression of D-type cyclins (D1, D2, and D3) is up-regulated, and these cyclins bind to Cdk4 or Cdk6, forming the active cyclin D-Cdk4/6 complex, which phosphorylates and inactivates the protein retinoblastoma (pRb). Phosphorylation of pRb allows progression into the S phase (Stiegler and Giordano 2001) . E-type cyclins (E1 and E2) are expressed in late G1 and bind to Cdk2 to accelerate entry into the S phase (Resnitzky et al. 1994 ). B-type cyclin (B1) is accumulated through S and G2 phases and forms a complex with Cdk1, which controls G2/M transition and mitosis (Nurse 1990 ). The Cdk1/cyclin B1 enzyme activity depends on the expression level of cyclin B1. Considering that over 80 % of cells were accumulated at the G2/M phase at 24 h after eupatorin exposure (Fig. 2) , it appears that eupatorin may affect G2/M regulatory proteins. To test this hypothesis, expression levels of cyclin D1 and cyclin B1 were examined in eupatorin-treated HeLa cells by immunoblotting. As shown in Fig. 3A , cyclin D1 levels decreased rapidly within 3 h of eupatorin exposure. In contrast, cyclin B1 levels increased, beginning at 6 h and continuing up to 24 h.
Tumor protein p53 is a tumor suppressor, regulating DNA repair, cell cycle arrest, and apoptosis. p53 accumulates in response to diverse cellular stress signals, including genotoxic damage (Giaccia and Kastan 1998) . Activated p53 induces growth arrest by upregulating the expression of cell cycle inhibitor p21, and it triggers apoptosis by upregulating the expression of pro-apoptotic proteins such as Bax, Puma, and Noxa (Levine 1997) . We thus investigated whether eupatorin induces the accumulation of p53 protein. It is known that phosphorylation of p53 at serine-15 leads to p53 stabilization and enhances (2016) 59(2): 193-199 195 transactivation of p53 target genes. Eupatorin increased total and phosphorylated (serine-15) levels of p53 protein, as well as p21 and Bax levels in a time-dependent manner ( Fig. 3B) , suggesting that p53 is transactivated upon eupatorin treatment.
Caspases are a family of cysteine proteases involved in the initiation and progression of apoptosis (Danial and Korsmeyer 2004) . Procaspases are activated by proteolytic cleavage by other caspases. There are two classes of caspases: (i) initiator caspases, such as caspase-8 and -9, which cleave and activate pro-forms of effector caspases and (ii) effector caspases, such as caspase-3 and -7, which cleave other cellular protein substrates to trigger the apoptotic process. Since Bax is involved in mitochondriamediated apoptosis (Oltvai et al. 1993) , we determined whether eupatorin has the potential to activate caspases. HeLa cells were treated with 20 lM eupatorin and caspase-7 cleavage was examined. Immunoblot analysis showed that eupatorin increased the cleavage of caspase-3, caspase-7, and poly(ADP-ribose) polymerase (Fig. 3B) .
During the early stage of apoptosis, translocation of the lipid phosphatidylserine (PS) translocates from the inner to the outer plasma membrane. Annexin V preferentially binds PS with high affinity (Andree et al. 1990 ). To determine whether PS appeared in the outer leaflet of the cell membrane after eupatorin treatment, FITC-Annexin V was stained. A fluorescent dye PI which binds to nucleic acids was used to counterstain dead cells. As shown in Fig. 4 , the proportion of PI-negative and Annexin V-positive cells (early apoptotic cells; lower right quadrant) increased from 7 to 38 % after 48 h of exposure to eupatorin. Notably, PI and Annexin V double-positive cells (late apoptotic and/or dead cells; upper right quadrant) increased from 16 to 71 %. These data suggested that eupatorin triggered cell death through apoptosis. While eupatorin accumulated the p53 level, we investigated the role of p53 in eupatorin-induced apoptosis by using wild-type HCT116 human colorectal carcinoma cells which express wild-type p53 (Widel et al. 2015 ) and p53-null variant cells (p53 -/-) (Bunz et al. 1999) . As shown in Fig. 5A , p53 and p21 protein levels were increased in response to eupatorin treatment in wild-type HCT116 cells (p53 ?/? ) but not in p53-null HCT116 cells (p53 -/-). Interestingly, Bax protein expression in wild-type HCT116 cells was similar to that in p53-null HCT116 cells. These data suggest that eupatorin-induced p21 expression is p53-dependent, while Bax expression is involved in a p53-independent mechanism. We further determined the role of p53 in eupatorin-induced apoptosis in p53-null HCT116 cells. As shown in Fig. 5B , treatment with eupatorin increased population of the late apoptotic and/or dead cells (upper right quadrant; PI and AV double-positive) from 14 to 37 % and 5 to 32 % in p53-wild-type and p53-null HCT116 cells, respectively. These data suggest that eupatorin could trigger apoptosis irrespective of p53 status.
Previous studies have demonstrated that Egr-1 up-regulates the pro-apoptotic Bax gene independently of p53 (Zagurovskaya et al. 2009 , Shin et al. 2012 . Egr-1 is a Cys2/His2-type zinc-finger transcription factor that regulates cell growth, differentiation, development, and death (Thiel and Cibelli 2002) . We next examined whether eupatorin induces the expression of Egr-1 in HCT116 cells. As shown in Fig. 5C , Egr-1 protein levels were increased upon eupatorin treatment in both wild-type and p53-null HCT116 cells. To evaluate the role of Egr-1 in the Whole-cell lysates were subjected to immunoblotting using antibodies against cyclin D1 and cyclin B1. GAPDH antibody was used as an internal control to demonstrate equal protein loading. (B) HeLa cells were treated with 20 lM eupatorin for various lengths of time (0, 6, 12, and 24 h) , and whole-cell lysates were then subjected to immunoblotting using antibodies against the indicated proteins. GAPDH antibody was used as an internal control to demonstrate equal protein loading transcriptional activation of the Bax gene, wild-type Bax promoter, pBax-Luc(-478/?4), and mutant promoter disrupting Egr-1-binding site, pBax-Luc(-478/?4)mtEgr1, were transfected into HeLa cells and measured luciferase promoter reporter activity following eupatorin treatment (Fig. 5D ). We found that eupatorin treatment resulted in a 3.5-fold activation of wild-type Bax promoter activity; however, this activation was significantly reduced to around a half of wild-type reporter activity for the Egr-1 mutant reporter. These data suggest that Egr-1 may play a role in regulating Bax gene expression upon eupatorin treatment. Collectively, our results suggest that eupatorin triggers cytotoxic effects by a mechanism involving the p53-mediated p21 expression and p53-independently Egr-1-mediated Bax expression. Among p53 effectors, Bax is a pro-apoptotic member of the Bcl-2 family protein, which is a key factor involved in the disruption of mitochondrial membrane and the activation of caspase-9 and has been shown to play an important role in p53-mediated apoptosis (Miyashita and Reed 1995) . In addition to p53-dependent pathway, the expression of Bax can be up-regulated by several other transcription factors, including Egr-1 (Zagurovskaya et al. 2009; Shin et al. 2012) . Our data showed that induction of the Bax protein occurred following eupatorin treatment in both wild-type and p53-null HCT116 cells. Furthermore, eupatorin-induced apoptosis were not apparently abolished in p53-null HCT116 cells. As induction of the Bax protein is likely to be resulted in Egr-1 upregulation, eupatorin-induced apoptosis would most likely proceed regardless of the cellular status of p53 through p53-independent pathway. Given that the p53 gene is mutated or deficient in a broad spectrum of different tumor types, eupatorin-induced apoptosis in a p53-independent manner may provide new insights into the molecular mechanisms responsible for the antitumor effects of flavone derivatives.
In summary, eupatorin triggers cytotoxicity in HeLa human cervical carcinoma cells through induction of cell cycle arrest at the G2/M phase, followed by caspase- Fig. 4 Effect of eupatorin on apoptosis. HeLa cells were treated with 20 lM eupatorin for 48 h and then stained with FITC-Annexin-V and propidium iodide (PI). Cells were harvested, washed, and analyzed for fluorescence intensity. Scatter plots (top panels) show the FITC-Annexin V intensity (x-axis) versus that of PI (y-axis). Histograms (bottom panels) show the Annexin V and PI doublepositive cell counts (%) mediated apoptosis. Our findings suggest that eupatorin may be an attractive natural compound for further development as a cancer chemopreventive and as an adjuvant chemotherapeutic agent. ?/? or p53 -/-HCT116 cells were treated with 20 lM eupatorin and subjected to immunoblotting using antibodies against the indicated proteins. GAPDH antibody was used as an internal control to show equal protein loading. (D) HeLa cells were transfected with 0.2 lg Bax promoter construct, wild-type pBax-Luc(-478/?4) or pBax-Luc(-478/?4)mtEgr1. The core Egr-1-binding motif is enclosed in a box. After 48 h, cells were treated with 20 lM eupatorin for 8 h and luciferase activities were measured. Data represent the mean ± SD of three independent experiments, each performed in triplicate (**P \ 0.01)
